NCT02454699View on ClinicalTrials.gov

Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 10, 2015

Primary Completion Date

April 1, 2017

Study Completion Date

December 1, 2017

Conditions
Cytomegalovirus Infection
Interventions
DRUG

MBX400

MBX-400, a white to off-white crystalline powder, will be given orally x 7 days to 4 cohorts. Cohort 1 receives 100 mg/day, Cohort 2 receives 350 mg, Cohort 3 receives 750 mg, Cohort 4 receives 1000 mg.

OTHER

Placebo

Placebo capsules are supplied as white opaque, hard gelatin capsules filled with microcrystalline cellulose. 2 subjects from each cohort receive Placebo orally once per day x 7 days.

Trial Locations (1)

30030-1705

Emory Vaccine Center - The Hope Clinic, Decatur

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02454699 - Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers | Biotech Hunter | Biotech Hunter